Key Takeaways
- Margin recovery leads the quarter: EBITDA margin rebounded over 600 bps sequentially to 23.9% as price revisions passed through, though raw material costs are not yet normalized.
- H1 revenue already exceeds full-year FY26: Consolidated H1 FY27 revenue of ₹193.17 crores surpassed all of FY26, driven by platform transformation and group consolidation.
- CDMO commercial supply delayed, not derailed: Validation quantities shipped for the first molecule, but commercial supply pushed 1–2 months to end of Q3 or first month of Q4 FY27; CDMO revenue excluded from all guidance.
- Capital raise and full ownership moves forward: Board finalized up to ₹250 crores fund infusion, and share swap to acquire remaining stakes in Bizotic and Apiqo nears completion.
- What to watch next quarter: Whether CDMO molecule 1 begins commercial supply, the pace of Rajkot greenfield construction through the December public hearing, and progress toward the 25%–26% full-year EBITDA margin target, which management hopes to reach.
Margin Recovery & Profitability
- Sequential rebound driven by pricing: EBITDA margin recovered to 23.9% in Q2 FY27 from 17.8% in Q1 FY27, an improvement of over 600 basis points sequentially, because price revisions were successfully passed through to customers even as raw material prices stayed elevated post the March geopolitical situation.
- Operating leverage flowing through: Revenue grew 20.6% QoQ and 102.3% YoY, reflecting the price revision impact as contracts were repriced.
- Consolidated margin structure is blended lower: Apiqo Organics operates at sustainable EBITDA of 20%–23% and PAT of 11%–13% as a volume business with lower regulatory burden, while Anlon Healthcare standalone runs at 25%–27% EBITDA and 13%–14% PAT.
- Full-year margin target within reach: Management expects to achieve at least 25%–26% EBITDA margin in full-year FY27 results based on current projections and orders in hand, with a sustainable band of 25%–27% for FY28 if the situation remains the same.
- Working capital trade-off supports profitability: Payable days run at ~40 days because management buys with short payment terms to secure better material prices, which benefits PAT and profitability despite higher interest cost; 90-day credit is available but at higher material cost plus interest.
Punitkumar Rasadia: "The cost of material is increased along with the interest rate also is if we are having the cash in hand and we are getting with the lower credit terms, then we are getting the better price that can also be beneficial in increase our PAT and profitability."
CDMO: The Long-Gestation Bet
- First molecule progressing, commercial supply delayed: Validation quantities have been supplied for the first CDMO molecule, but commercial supply is now expected end of Q3 FY27 or first month of Q4 FY27, a 1–2 month delay from the original Q3 FY27 target.
- Molecules 2 and 3 further out: Commercialization for the second and third CDMO molecules is expected after H1 FY28.
- Revenue excluded from all guidance: CDMO contribution is not factored into FY27 (₹380–400 crores) or FY28 (₹650–700 crores) revenue guidance; those figures are based on existing business and sure-shot customer commitments only.
- Molecule 1 meaningful only by Q4 FY28: Significant revenue contribution from the first CDMO molecule is expected by Q4 FY28, with clarity arriving in the last quarter after the customer assesses market and patient response.
- Durability argument rests on long development cycles: A CDMO molecule typically takes 3–4 years from development to commercial revenue, which management argues makes the relationship durable once established.
Punitkumar Rasadia: "I would reiterate that CDMO molecule typically takes a minimum of 3 to 4 years from development to commercial revenue, which is precisely what makes this relationship durable once established."
Expansion & New Business Lines
- Rajkot greenfield on track with a caveat: Construction has started, the first floor is expected finished by end of November, and equipment installation will begin in parallel; commissioning is targeted for Q1 FY28 with revenue from Q2 FY28, though a public hearing in December could cause 1–2 months delay if postponed by the regulatory agency.
- Anlon Biologics incorporated: The new subsidiary will develop and manufacture peptides, oligonucleotides, biosimilars and biological compositions, pursuing an end-to-end finished dosage formulation CDMO model; management is already discussing tie-ups with potential customers.
- Anlon Medicos enters finished dosage: Formerly Remember India, this subsidiary brings tablet and capsule capabilities and access to over 30 formulation dossiers; operations begin Q3 FY27 targeting domestic retail and hospital markets, with first revenue now expected Q4 FY27 due to regulatory approval pendency.
- Injectable facility expansion underway: Expansion at Anlon Medicos has started, expected completion by end of next year.
- Apiqo Organics adds industrial chemicals vertical: A new fine and industrial chemicals vertical has opened as a revenue stream outside pharmaceuticals, operating its own established product range.
- Apiqo capacity expansion: Activity has started on a 500–600 MTPA expansion, expected completion Q1 FY28; spare land is available, only a new block and equipment are needed since utilities and other facilities already exist.
- Post-expansion ambition: Anlon aims to become the world's largest manufacturer for Ketoprofen and Dexketoprofen.
Cash Flow & Balance Sheet
- Operating cash flow improved materially: Net cash used in operating activities reduced to ₹7.94 crores in H1 FY27, versus ₹79.44 crores for full FY26, because pending receivables were recovered significantly and customer credit terms were tightened from 130–140 days to 90–100 days.
- Commitment to full-year positive cash flow: Management has committed to deliver positive operating cash flow by end of FY27.
- Capital raise finalized in principle: The board has finalized a fund infusion of up to ₹250 crores; the exact figure and amount are yet to be decided, with planning expected to conclude before end of November, followed by an AGM.
- Term loan for ongoing capex: Management is approaching banks for a ~₹65–70 crores term loan for ongoing capex at Anlon Healthcare, with the remainder funded from internal accruals.
- Share swap nearing completion: In-principle approval from stock exchanges has been received for acquiring the remaining stakes in Bizotic and Apiqo; the allotment and swapping process is ongoing and expected to complete within the next 8–10 days.
- ROE decline explained: The downward trend reflects the acquisition of 4–5 companies whose operations started only 6–8 months ago; improvement is expected by FY27 as CDMO, formulation, and new higher-profitability API products begin contributing.
- Dividend assessment deferred: Management will evaluate the possibility by the last quarter after assessing cash availability and free cash flow post all capex and commitments; it is too early to commit.
Product Pipeline & Regulatory Moat
- DMF commercialization progressing: 4 products out of the targeted 5–7 have already been commercialized and validated, with filings ongoing.
- DMF filing cadence: 3 DMFs are almost done and will be filed by December; another 2–3 are planned by Q4 FY27, totaling ~6 filings in FY27, though one may be delayed 1–2 months due to complexity of stability data.
- Ketoprofen U.S. DMF on hold: The filing is awaiting a trigger from a U.S. FDA customer which has not started; there is no plan to file the DMF directly for U.S. Ketoprofen.
- Loxoprofen topical gel in regulatory pipeline: Filings are underway with CDSCO and DCGI for the Indian market; DCGI approval is expected by at least Q1 FY28, after which pan-India marketing with own formulation begins.
- Regulatory barrier as competitive advantage: Management argues that registration, not price, is the decisive factor, since a new entrant must build the chemistry file with the DMF and clear customer audits in each jurisdiction before it can even quote.
- China positioning: Management states China is not a competitor in Anlon's products, and that Anlon focuses on products where it is strong in chemistry and handling hazardous materials; cost-wise, Anlon claims to be at least 10% cheaper than Chinese prices, with quality at par or better and the advantage of China Plus One policy.
Punitkumar Rasadia: "In this business, registration rather than price is getting factored. A new entrant must build the chemistry file with the DMF and clear customer audits in each jurisdiction before it can even quote. That is what makes our registered supplier status durable."
Revenue Mix & Capacity
- H1 revenue milestone: Consolidated H1 FY27 revenue of ₹193.17 crores already exceeded full-year FY26 revenue, driven by the broader platform transformation and consolidation of group entities.
- Group revenue composition: Anlon Healthcare standalone contributed 44.6% of consolidated H1 revenue, Apiqo Organics 43.7%, and Bizotic Lifescience 11.7%.
- Standalone product mix: Within Anlon standalone, intermediates dominated at 81.1% of revenue, API at 17.1%, with the balance from nutraceutical and other products; Ketoprofen API, when used as raw material for Dexketoprofen manufacturing, is classified as intermediate rather than API, explaining the skew.
- API and intermediate margins similar: Gross margin for both segments is ~35%, with EBITDA at ~35% of that gross margin; management stated there is not much difference between the two segments.
- Consolidated capacity utilization at 65%–67%: Anlon standalone is at optimum 85%–86%, so further growth requires new expansion; consolidated utilization is expected to remain the same for the next 2 quarters.
- Medical devices revenue potential: The surgical implants and medical devices business is expected to generate ₹70–80 crores in revenue within the next 3 years, with EBITDA margins better than the pharma and medicine business.
- Anlon Medicos peak revenue: Existing tablet and capsule capacity is expected to reach ₹80–90 crores at peak; Loxoprofen topical gel could deliver 2x or 3x that revenue once approved and marketed pan-India, with approval anticipated by Q1 FY28.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 full-year revenue | ₹380 crores to ₹400 crores; management stated they are "almost in line with that target" | FY27 full year |
| FY28 full-year revenue | ₹650 crores to ₹700 crores, based on ongoing expansion projects and existing business with sure-shot customer commitments | FY28 full year |
| FY27 EBITDA margin | At least 25%–26% for full-year FY27 results, based on current projections and orders in hand | FY27 full year |
| Sustainable EBITDA margin | 25%–27% consolidated, once remaining price revisions and integration benefits realize | Ongoing from FY27 |
| Positive operating cash flow | Deliver positive operating cash flow on an annual basis | By end of FY27 |
| CDMO molecule 1 commercial supply | Commercial supply to begin | End of Q3 FY27 or first month of Q4 FY27 |
| CDMO molecule 1 meaningful revenue | Significant revenue contribution expected | By Q4 FY28 |
| CDMO molecules 2 and 3 commercialization | Commercial supply to begin | After H1 FY28 (minimum 6–8 months from now) |
| Rajkot greenfield commissioning | Commissioning and revenue contribution to begin | Commissioning Q1 FY28; revenue from Q2 FY28 |
| Anlon Medicos first revenue | First revenue from finished dosage formulations | Q4 FY27 (delayed from Q3 FY27) |
| Anlon Biologics first revenue | First revenue from peptides, oligonucleotides, biosimilars | Q4 FY28 |
| Share swap completion | Full ownership of Bizotic and Apiqo via allotment and swapping | Within next 8–10 days |
| DMF filings in FY27 | ~6 DMFs to be filed; 3 by December, remainder by February–March | FY27 |
| Loxoprofen topical gel approval | DCGI approval expected | At least Q1 FY28 |
| Apiqo capacity expansion | 500–600 MTPA expansion completion | Q1 FY28 |
| Injectable facility at Anlon Medicos | Expansion completion | By end of next year |
| Medical devices revenue | ₹70–80 crores revenue | Within next 3 years |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹105.61 cr, +102.3% YoY and +20.6% QoQ |
| H1 FY27 revenue from operations | ₹193.17 cr, +125.9% YoY; exceeded full-year FY26 revenue |
| EBITDA | ₹25.24 cr, +84.1% YoY and +61.9% QoQ |
| EBITDA margin | 23.9%, +610 bps QoQ from 17.8% in Q1 FY27; raw material cost pass-through effected |
| H1 FY27 EBITDA margin | 21.1% |
| Profit after tax | ₹17.18 cr, +84.4% YoY |
| H1 FY27 profit after tax | ₹25.46 cr, +97.9% YoY |
| FY27 full-year revenue guidance | ₹380 cr to ₹400 cr, maintained |
| FY28 full-year revenue guidance | ₹650 cr to ₹700 cr, excluding CDMO and medical devices contribution |
| Consolidated capacity utilization | 65% to 67%; Anlon standalone at 85% to 86% (optimum) |
| Installed manufacturing capacity (group) | ~1,900 to 2,000 MTPA, vs 400 MTPA at parent previously; Rajkot greenfield adding ~1,200 MTPA commissioning Q1 FY28 |
| Net cash used in operating activities (H1 FY27) | ₹7.94 cr, vs ₹79.44 cr for full-year FY26; working capital outflow reduced materially |
| Receivable days | ~123 days annualized (per an analyst's math); credit terms reduced to 90–100 days from 130–140 days |
| DMFs filed with global authorities | 21; 4 products commercialized and validated; 3 additional filings planned by December, 2–3 more by Q4 FY27 |
| CDMO molecules under development | 3 molecules for 2 global innovator companies; first commercial supply delayed to end-Q3 or early Q4 FY27; molecules 2 and 3 commercialization expected after H1 FY28 |